Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease - sprookjes - yvandenbroek - TriplyDB

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

http://www.wikidata.org/entity/Q28259585

about

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal Polyphenol Stilbenes: Molecular Mechanisms of Defence against Oxidative Stress and Aging-Related Diseases Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art Aberrant insulin signaling in Alzheimer's disease: current knowledge Synaptic dysfunction and septin protein family members in neurodegenerative diseases The dendritic hypothesis for Alzheimer's disease pathophysiology.Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood Lipid microdomain modification sustains neuronal viability in models of Alzheimer's disease Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease.Diabetes and Cognitive Impairment.Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1 Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain.Insulin action in brain regulates systemic metabolism and brain function.The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer's disease: an overview of pre-clinical studies and translational perspectives in clinical practice.Insulin Attenuates Beta-Amyloid-Associated Insulin/Akt/EAAT Signaling Perturbations in Human Astrocytes An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease.Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease.Effects of treadmill exercise on brain insulin signaling and β-amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats.A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease New function of the adaptor protein SH2B1 in brain-derived neurotrophic factor-induced neurite outgrowth Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease.miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling.Neuronal DNA damage response-associated dysregulation of signalling pathways and cholesterol metabolism at the earliest stages of Alzheimer-type pathology Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction.Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo Glycogen and amyloid-beta: key players in the shift from neuronal hyperactivity to hypoactivity observed in Alzheimer's disease?Insulin and IGF1 signalling pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and modulation of the receptors.Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease Brain metabolic dysfunction at the core of Alzheimer's disease.Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity.Metabolic Characterization of Intact Cells Reveals Intracellular Amyloid Beta but Not Its Precursor Protein to Reduce Mitochondrial Respiration.Capsaicin reduces Alzheimer-associated tau changes in the hippocampus of type 2 diabetes rats Melatonin Therapy in Patients with Alzheimer's Disease.Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.Synaptosomal Protein of 25 kDa (Snap25) Polymorphisms Associated with Glycemic Parameters in Type 2 Diabetes Patients.

P2860

Q24601034-8AD29E07-B3BA-4001-B2BC-CC2E27BEC6B2 Q26382049-0AEA41FC-3FC5-46ED-AF14-3A3430F468C9 Q26783344-E31DEB97-480A-45A6-97E6-A348503ED662 Q26800956-BEFB26FC-8B3C-4F69-9B14-5861BF513817 Q26830845-590168F7-59DF-43D2-BCDE-3D2E1722B622 Q27024222-76FD8B58-28AC-4690-8BDB-0DA63232B9A7 Q27026829-4D720077-1C9D-4DE4-B6E1-073794AFEE0D Q27687404-1391B1AE-CAC3-4747-A6CD-C2A59F418686 Q28079442-6B5E3363-893B-4EB8-A8E9-094A592E2F34 Q28278644-B8FB168E-F8F9-4BE9-9075-5102F8BD6717 Q30367032-39FF9418-0FF7-44B2-9462-B16CE758B67F Q30573779-0188F087-5FDE-4CCD-8A93-DA1DF391D35B Q31108663-2F00E53C-299A-49BC-A9AA-007078EB1C29 Q31119662-3110C9CE-0340-4186-AD3A-B8175D4F7DF1 Q33362745-036AFA15-22D3-45A6-A738-F876398EBA8D Q33687674-289D404C-2714-479B-BC8E-D2A594229A3E Q33775384-DD8FF976-7D6B-4BF0-9B88-1059F3C6EB55 Q33789365-05F57950-1473-4DEA-88B7-5A6635F91B79 Q33814399-ED84E489-6FEE-4A96-8796-EF4BDAB1141C Q33887259-42FBE844-C23B-4B05-A967-C20BE3ABAE2A Q34126021-ECB93967-DE0F-4C66-9509-ACAACC7EF391 Q34544243-39308AE0-D08C-4CC3-A7DF-CB3844C92F48 Q34563467-3E4BE06A-1EFB-4CE0-94BD-19B3B18E29C1 Q34989806-57C8AC66-75FF-40F8-9E69-A0AD2A1969EF Q35048581-6A10A276-6C31-4A6D-BB32-24BFE48DAF07 Q35052443-76B6C683-B9B8-4E83-AC3A-69D72AE02105 Q35100268-00F40558-2033-4584-A730-5E1F6856B6CE Q35669877-05B13EC8-B1F8-4F4D-850C-0E8F69E7F3DF Q35776248-71584E7C-F439-4C1B-B66B-A980EA887B10 Q35836136-F231A35B-CBBB-4188-A5BF-FD3DABFDA602 Q35969643-BE5FCE1B-B6A5-4ABF-ABB7-20A43FCD5AC3 Q35986995-633CE862-43B7-4BDB-8E90-F1258DD3F40D Q35997824-800EC08E-3581-4255-9CAA-61B229F84E2F Q35997881-E4CC0296-0B19-4A5B-BA82-25E4A65549BC Q36186276-4BCEA0A9-5F00-4C45-A43F-79256DEFA9A5 Q36231595-FEA28B64-C4D8-4CD2-B4B0-087C04630877 Q36287492-04CA6E22-D8F8-4D06-BB58-8A3FC978081B Q36335048-3DE3612A-A0F5-4F7A-9A3D-20F4C06AE5D4 Q36355644-4FBFC20C-433A-46AB-8FF7-F0AAC44A0D0C Q36392197-1BC55088-7D80-476D-A739-D0DA8D536C99

P2860

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

http://www.wikidata.org/entity/Q28259585

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@ast

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@en

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@nl

type

label

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@ast

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@en

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@nl

prefLabel

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@ast

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@en

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@nl

P1433

Q28259585-7765DD75-A054-4E0C-9F9C-FECC3FD4C3C2

P1476

Q28259585-5FEF7EE6-E260-4FE2-A601-EF8E5A14682A

P2093

Q28259585-93DE82B3-4185-47D4-A427-D742D96CD8B4

P275

Q28259585-A02C59A6-E767-4AEA-BCC0-C12505D14E5F

P2860

Q28259585-0043ADF3-0046-44C7-A142-F381FE06ED87

Q28259585-00971BBF-185C-411D-BC30-E6777CFDCCBE

Q28259585-00D9C9AD-A619-41C9-92D7-7024ACC7BE60

Q28259585-00F68874-5A00-4BA8-A142-831EF4E6B7F8

Q28259585-01420329-CC0F-43DE-AFB9-56583AE1470A

Q28259585-01675A9E-97EF-425D-8D2D-A294538C2E03

Q28259585-01B17F79-F85E-4C3E-B920-86E131160D2F

Q28259585-01DC8F6C-FBC6-4FE8-892F-4F7F202C5476

Q28259585-020D3DCC-F71B-4C4D-A528-DC0AA6432F97

Q28259585-04754568-CA2F-436A-B45E-3D277CCC6B74

P304

Q28259585-F5C99CD0-F858-4342-8AD0-F970CEBCC631

P31

Q28259585-6370F390-9317-49E2-93CE-98DFD5B17135

Q28259585-85F39790-8B0E-43EF-A120-ED9039B540B9

P3181

Q28259585-486E7DA9-16CC-4FB4-A62E-1729FFE09E36

P356

Q28259585-6DE1EDC2-6F9B-4A80-B114-4118C5AF54D9

P407

Q28259585-40108595-D443-45BE-BAD8-E4C84DE02D08

P433

Q28259585-38BFB101-C220-479D-A19F-4C193B2A5B17

P478

Q28259585-B977FE27-1051-4727-87EF-A2D660D80534

P5008

Q28259585-8A789AB7-6F9A-4C09-B945-8C344A049E07

P577

Q28259585-2D616DB0-9055-4425-ADF1-B5EE8C4B94A6

Q28259585-D104D116-3255-473E-8CAB-46A447B1692F

P5875

Q28259585-5266EF94-6196-4ADF-935C-6E7C0A3B5802

P698

Q28259585-4686B9A7-4C0C-4792-B359-C8EF218D216B

P921

Q28259585-3B4D727D-EB40-40A8-A883-360A5FF680D0

Q28259585-44A701D2-82CF-42D0-ADA2-EB5B5D356B69

Q28259585-6983EA4E-F9AA-40A3-95F3-EA93A6BAB63D

Q28259585-9F70EC0E-8049-467F-9B4B-2FE06FE90566

Q28259585-AF3A3276-A367-4FB1-B741-95ACF6B97C5B

Q28259585-B9226AE2-8F1E-4368-BDA3-F95A5AA26C90

Q28259585-DE9139C1-E29C-4A05-BF4E-73552FCDA79F

Q28259585-E00859FE-87E1-4B9C-8890-40DB8FA1EFC6

P932

Q28259585-76DECD13-F1D5-4EEE-BDCE-35E74EFAECE2

P3181

P356

156720512799015037

P1433

Current Alzheimer Research

P1476

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

@en

P2093

Suzanne M de la Monte

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Effects of Ginkgo biloba in dementia: systematic review and meta-analysis

Role of imaging techniques in the diagnosis of dementia

Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease

Diet and Alzheimer’s disease

Statins for the treatment of dementia

Ginkgo biloba for cognitive impairment and dementia

Omega-3 fatty acids: potential role in the management of early Alzheimer's disease

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

GSK-3: tricks of the trade for a multi-tasking kinase

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study

P304

35-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

82675

http://www.w3.org/2001/XMLSchema#string

P356

10.2174/156720512799015037

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221827935

http://www.w3.org/2001/XMLSchema#string

P698

22329651

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

metabolic disease

physiological phenomena

P932

3349985

http://www.w3.org/2001/XMLSchema#string